Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model

• Published in: PLoS medicine 2007-05, Vol.4 (5), p.e182
• Main Authors: Watase, Kei, Gatchel, Jennifer R, Sun, Yaling, Emamian, Effat, Atkinson, Richard, Richman, Ronald, Mizusawa, Hidehiro, Orr, Harry T, Shaw, Chad, Zoghbi, Huda Y
• Format: Article
• Language: English
• Subjects: Animals; Antimanic Agents - pharmacology; Ataxia; Ataxin-1; Ataxins; Brain research; Cognition & reasoning; Cognitive ability; Dendrites - enzymology; Dendrites - pathology; Disease; Drug therapy; Female; Gene expression; Genetics and Genomics; Glycogen Synthase Kinase 3 - metabolism; Glycogen Synthase Kinase 3 beta; Hippocampus - pathology; Influence; Lithium; Lithium Carbonate - pharmacology; Male; Maze Learning - drug effects; Memory; Memory - drug effects; Mice; Mice, Inbred C57BL; Mice, Neurologic Mutants; Motor Activity - drug effects; Motor Neuron Disease; Nerve Tissue Proteins - genetics; Neurodegeneration; Neurological Disorders; Neurological research; Neurology; Neurons; Neuroscience; Nuclear Proteins - genetics; Pathogenesis; Phosphorylation - drug effects; Protein Methyltransferases - genetics; Proteins; Proto-Oncogene Proteins c-akt - metabolism; RNA, Messenger - metabolism; Spinocerebellar ataxia; Spinocerebellar Ataxias - drug therapy; Spinocerebellar Ataxias - genetics; Spinocerebellar Ataxias - pathology; Toxicity
• ISSN: 1549-1676; 1549-1277; 1549-1676
• DOI: 10.1371/journal.pmed.0040182

Spinocerebellar ataxia type 1 (SCA1) is a dominantly inherited neurodegenerative disorder characterized by progressive motor and cognitive dysfunction. Caused by an expanded polyglutamine tract in ataxin 1 (ATXN1), SCA1 pathogenesis involves a multifactorial process that likely begins with misfolding of ATXN1, which has functional consequences on its interactions, leading to transcriptional dysregulation. Because lithium has been shown to exert neuroprotective effects in a variety of conditions, possibly by affecting gene expression, we tested the efficacy of lithium treatment in a knock-in mouse model of SCA1 (Sca1(154Q/2Q) mice) that replicates many features of the human disease. Sca1(154Q/2Q) mice and their wild-type littermates were fed either regular chow or chow that contained 0.2% lithium carbonate. Dietary lithium carbonate supplementation resulted in improvement of motor coordination, learning, and memory in Sca1(154Q/2Q) mice. Importantly, motor improvement was seen when treatment was initiated both presymptomatically and after symptom onset. Neuropathologically, lithium treatment attenuated the reduction of dendritic branching in mutant hippocampal pyramidal neurons. We also report that lithium treatment restored the levels of isoprenylcysteine carboxyl methyltransferase (Icmt; alternatively, Pccmt), down-regulation of which is an early marker of mutant ATXN1 toxicity. The effect of lithium on a marker altered early in the course of SCA1 pathogenesis, coupled with its positive effect on multiple behavioral measures and hippocampal neuropathology in an authentic disease model, make it an excellent candidate treatment for human SCA1 patients.